A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model

Molecular Cancer Therapeutics

Volumn 17, Issue 7, 2018, Pages 1494-1503

  Iwata, Tomomi Nakayama ^a   Ishii, Chiaki ^a   Ishida, Saori ^a   Ogitani, Yusuke ^a   Wada, Teiji ^a   Agatsuma, Toshinori ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD86 ANTIGEN; DS 8201A; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; TRASTUZUMAB DERUXTECAN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; CAMPTOTHECIN; CD274 PROTEIN, HUMAN; DS-8201A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; EXATECAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TRASTUZUMAB;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; IN VIVO STUDY; MDA-MB-453 CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR CELL; TUMOR IMMUNITY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CD8+ T LYMPHOCYTE; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; BREAST NEOPLASMS; CAMPTOTHECIN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCONJUGATES; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTOR, ERBB-2; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85049627755     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-17-0749     Document Type: Article

References (37)

1. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the designofnovel and rationale-based combined treatments against cancer. Cell Death Differ 2014; 21: 15-25.
2. Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol 2016; 102:1-6.
3. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10.
4. Martin K, Müller P, Schreiner J, Prince SS, Lardinois D, Heinzelmann-Schwarz VA, et al. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol Immunother 2014; 63:925-38.
5. McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, et al. The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy. JNCI: J Nat Cancer Inst 2017:djx257-djx.
6. Kitai Y, Kawasaki T, Sueyoshi T, Kobiyama K, Ishii KJ, Zou J, et al. DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J Immunol 2017; 198:1649-59.
7. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016; 22:5097-108.
8. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 2016; 107: 1039-46.
9. Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol 2017; 18:1512-22.
10. Tsurutani J, Doi T, Iwata H, Takahashi S, Modi S, Tamura K, et al. Updated results of phase1 study of DS-8201ainpatients with HER2 expressing non-breast, non-gastric malignancies. Ann Oncol 2017; 28:mdx367.042.
11. Doi T, Iwata H, Tsurutani J, Takahashi S, Park H, Redfern CH, et al. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors. J Clin Oncol 2017; 35:108.
12. Menon S, Shin S, Dy G. Advances in cancer immunotherapy in solid tumors. Cancers 2016; 8:106-26.
13. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64.
14. Wolchok JD PD-1 blockers. Cell 2015; 162:937.
15. Swart M, Verbrugge I, Beltman JB. Combination approaches with immune-checkpoint blockade in cancer therapy. Front Oncol. 2016; 6: 233.
16. Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol 2016; 39:23-9.
17. Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kb to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 2015; 75:5034-45.
18. Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med 2015; 7:315ra188.
19. Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, et al. Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res 2017; 77:2686-98.
20. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018; 131:1183-94.
21. Nakada T, Masuda T, Naito H, Yoshida M, Ashida S, Morita K, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett 2016; 26:1542-5.
22. Gabrysiak M, Wachowska M, Barankiewicz J, Pilch Z, Ratajska A, Skrzypek EWA, et al. Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo. Oncol Rep 2016; 35:3151-8.
23. Penichet ML, Challita PM, Shin SU, Sampogna SL, Rosenblatt JD, Morrison SL. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci 1999; 49:179-88.
24. Zhao L, Tong Q, Qian W, Li B, Zhang D, Fu T, et al. Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP. Blood 2013; 122:4230-6.
25. Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunoh is tochemi calassay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002; 117:81-9.
26. DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res 2011; 13:R44.
27. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-6.
28. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48.
29. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993; 11:571-611.
30. Wortis HH, Burkly L, Hughe D, Roschelle S, Waneck G. Lack of mature B cells in nude mice with X-linked immune deficiency. J Exp Med 1982; 155:903-13.
31. Wortis HH, Burkly L, Hughes D, Roschelle S, Waneck G. Lack of mature B cells in nude mice with X-linked immune deficiency. J Exp Med 1982; 155:903-13.
32. Clark EA, Shultz LD, Pollack SB. Mutations in mice that influence natural killer (NK) cell activity. Immunogenetics 1981; 12:601-13.
33. Mizumoto N, Gao J, Matsushima H, Ogawa Y, Tanaka H, Takashima A. Discovery of novel immunostimulants by dendritic-cell-based functional screening. Blood 2005; 106:3082-9.
34. Andersen MH, Schrama D, thor Straten P, Becker JC. Cytotoxic T cells. J Invest Dermatol 2006; 126:32-41.
35. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci 2011; 108:7142-7.
36. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-70.
37. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016; 17:e254-e62.